Literature DB >> 7687035

Effect of chemoradiotherapy using ACNU, vincristine, and nicardipine with high-dose irradiation on malignant astrocytomas.

S Genka1, N Shitara, H Nakamura, K Takakura.   

Abstract

Fifty-two patients with malignant astrocytoma were treated with cellular synchronization radiation therapy at the University of Tokyo Hospital between 1977 and 1989. Twenty-five patients (Group 1) received 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU), vincristine, and 60 Gy of irradiation, and 27 patients (Group 2) ACNU, vincristine, the Ca-channel blocker nicardipine, and 72 Gy of irradiation. Median survival times for Groups 1 and 2 were 15 and 30 months, respectively. Although there was no significant difference, Group 2 achieved longer survival with 1-, 2-, and 3-year survival rates of 85.2, 65.8, and 46.9% compared to rates of 66.7, 40.0, and 26.7%, respectively, for Group 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687035     DOI: 10.2176/nmc.33.295

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  2 in total

1.  A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.

Authors:  T Beppu; Y Yoshida; H Arai; T Wada; M Suzuki; A Ogawa; S Hakozaki; N Kubo
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

2.  Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  In Sil Choi; Se Hoon Lee; Tae-You Kim; Jae Seug Bang; Sun Ha Paek; Suzy Kim; Il Han Kim; Dae Seog Heo; Yung-Jue Bang; Dong Gyu Kim; Hee-Won Jung; Noe Kyeong Kim
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.